📬 GYN Oncology Intelligence Digest — Week 2026-W39

CHMP issued positive opinions for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer and for senaparib first-line maintenance, while ASCO's first living guideline on recurrent ovarian cancer and new endometrial biomarker debates drove the week's discussion.

⚡ TL;DR

🐦 Twitter / 🦋 Bluesky

MMR status before the adjuvant plan: KEYNOTE-B21 and DUO-E subgroup numbers drive a testing-first argument in endometrial cancer — KEYNOTE-B21 was negative in all-comers with 22% DFS events in both arms, while the dMMR subgroup of n=281 had HR 0.31 (0.14-0.69)

Full details below ↓

📄 What's Being Published

Manuscripts:

Program-Level Neoadjuvant Chemotherapy Use and 10-Year Survival in Advanced Ovarian Cancer. — Powers Alex E R et al., JAMA Netw Open

This comparative effectiveness research examines the association between neoadjuvant chemotherapy adoption by US cancer programs and 10-year survival among patients with advanced ovarian cancer. The analysis positions the treating program — rather than the individual patient encounter — as the unit of inquiry for understanding long-term outcomes tied to surgical timing decisions.

Clinical bottom line: Program-level neoadjuvant chemotherapy adoption is the unit of analysis here, shifting the debate about upfront versus interval surgery from the individual patient to the treating program and its long-term survival record.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

MMR status before the adjuvant plan: KEYNOTE-B21 and DUO-E subgroup numbers drive a testing-first argument in endometrial cancer

KEYNOTE-B21 was negative in all-comers, with 22% DFS events in both arms, yet the dMMR subgroup (n=281) showed HR 0.31 (0.14–0.69) — a divergence that anchors the argument that MMR status cannot be an afterthought. In DUO-E, durvalumab cut progression risk 29%, and adding olaparib to maintenance cut it 45%; in pMMR disease — the majority of endometrial cancer — olaparib gave HR 0.57. The debate centers on whether dMMR/MSI-H, the subset where frontline chemo-immunotherapy earns durable benefit, should make MMR immunohistochemistry mandatory before any adjuvant or frontline systemic decision, given how differently dMMR and pMMR tumors behave across both trials.

Discussed by: @cancer_clinix, @cancer_clinix, @DrBarbiOnc

→ View representative tweet

🔥 Top Ranked Tweets

Dee Sparacio @womenofteal

#gyncsm Important Guidance for treatment on recurrence of OC.
Surgery ? Clinicians may discuss secondary cytoreduction for platinum-sensitive recurrences where complete gross resection is highly achievable.
[Quoting @JCO_ASCO: Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. Co-authored by @IslandJewelsena.

Read the full article. https://t.co/HakOT4v7QQ
#OvarianCancer #gyncsm]